FDA Calls For Class-Wide REMS For LABA Asthma Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
LABA asthma drugs are the latest group of medications to be hit with a class-wide Risk Evaluation and Mitigation Strategies requirement.
You may also be interested in...
In Replay Of Avandia Ban, Saudi Arabia First Regulator To Withdraw Long-acting Beta Agonists As Sole Therapy
The Saudi Arabia Food and Drug Authority appears to be the first regulatory agency to announce a withdrawal of long acting beta agonists that are not combined with corticosteroids, citing evidence of a linkage to an increased risk of death from asthma-related complications
In Replay Of Avandia Ban, Saudi Arabia Is First Regulator To Withdraw Long-acting Beta Agonists As Sole Therapy
Country's Food and Drug Authority appears to be the first regulatory agency to announce a withdrawal of long-acting beta agonists that are not combined with corticosteroids, citing evidence of a linkage to an increased risk of death from asthma-related complications.
In Replay Of Avandia Ban, Saudi Arabia Is First Regulator To Withdraw Long-acting Beta Agonists As Sole Therapy
Country's Food and Drug Authority appears to be the first regulatory agency to announce a withdrawal of long-acting beta agonists that are not combined with corticosteroids, citing evidence of a linkage to an increased risk of death from asthma-related complications.